Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma
Rota Caremoli, Elena
AffiliationUniv Arizona, Ctr Canc, Dept Med
MetadataShow full item record
PublisherBAISHIDENG PUBLISHING GROUP INC
CitationTumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma 2017, 23 (13):2448 World Journal of Gastroenterology
RightsCopyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractTumor biopsies may help to reliably distinguish hepatocellular carcinoma (HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients. Due to their frail status and sometimes fast-progressing disease, the performance status of patients with HCC progressing on first-line therapy can deteriorate quickly, preventing their enrollment in clinical trials. However, the challenge of identifying the proper patient at the proper time can be overcome by periodic inter-department meetings involving the key specialists taking care of HCC patients, and solid networks between research centers and referring institutions. An early planned biopsy would also facilitate timely inclusion of patients in biology-driven clinical trials. Ultimately, institution of multidisciplinary teams can optimize treatment choice, biopsy timing, and quick enrollment of patients in clinical trials, before their performance status deteriorates.
NoteOpen Access Publication.
VersionFinal published version
- Challenges of advanced hepatocellular carcinoma.
- Authors: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F
- Issue date: 2016 Sep 14
- Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
- Authors: Memon K, Kulik L, Lewandowski RJ, Gupta R, Ryu RK, Miller FH, Vouche M, Atassi R, Ganger D, Mulcahy MF, Salem R
- Issue date: 2013 Aug
- Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.
- Authors: Colombo M, Raoul JL, Lencioni R, Galle PR, Zucman-Rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P
- Issue date: 2013 Jun
- A multidisciplinary approach: group dynamics.
- Authors: Taddei TH
- Issue date: 2013 Jul
- Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
- Authors: Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group.
- Issue date: 2014 Dec 3